The LancetOpinion

Subcutaneous immunotherapy—a wolf in sheep's clothing?

Over the past decade, subcutaneous formulations of anticancer drugs—originally administered intravenously—have been ...

Seoul National University Hospital Identifies World's First Method to Prevent Radial Artery Occlusion After Surgery in Infants and Young Children

The research team led by Professors Young Eun Jang and Jung Bin Park from the Department of Anesthesiology and Pain Medicine ...
MedPage Today

Subcutaneous Ocrelizumab Not Inferior to IV Infusion

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window MILAN -- An ...
The American Journal of Managed Care

Subcutaneous Ocrelizumab and Hyaluronidase Approved for RMS, PPMS

Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The ...